CoChat

Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

The androgen-signaling pathway is critical to the development and progression of prostate cancer and androgen ablation is a mainstay of therapy for this disease. We performed a genome-wide expression analysis of human prostate cancer during androgen ablation therapy to identify genes regulated by androgen and genes differentially expressed after the development of resistance. Six hundred and fifty-four of 63,175 probe sets detected significant expression changes after 3 months of treatment with goserelin and flutamide. This included 149 genes that were also differentially expressed 36 hours after androgen withdrawal in LNCaP cells. These genes reflect the physiological changes that occur in treated tumors and include potential direct targets of the androgen receptor. Expression profiles of androgen ablation-resistant tumors demonstrated that many of the gene expression changes detected during therapy were no longer present suggesting a reactivation of the androgen response pathway in the absence of exogenous hormone. Therapy resistance was associated with differential expression of a unique set of genes that reflect potential mechanisms of reactivation. Specifically an up-regulation of the androgen receptor and key enzymes for steroid biosynthesis suggest that resistant tumors have increased sensitivity to and endogenous synthesis of androgenic hormones. The specific pathways of reactivation provide opportunities for classification of resistant tumors and targeted therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)63112-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 586

Metadata

Authors
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., Reuter, V., & Gerald, W. L.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2004-01
Volume
164
Issue
1
Pages
217-227
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2014476883
Cited by
577
References
31
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 25 · 2022: 8 · 2021: 15 · 2020: 15 · 2019: 19 · 2018: 21 · 2017: 30 · 2016: 27 · 2015: 34 · 2014: 38 · 2013: 51 · 2012: 51
FWCI
16.61
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • American Journal Of Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (U01 CA84999)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
prostate cancer, androgen deprivation therapy, treatment resistance, androgen receptor, androgen-regulated genes, goserelin, flutamide, androgen withdrawal, LNCaP cells, steroidogenesis, gene expression profiling
MeSH terms
Algorithms, Drug Therapy, Combination, Flutamide, Humans, Male, Prostatic Neoplasms, Gene Expression Regulation, Neoplastic, Goserelin, In Situ Hybridization, Fluorescence, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Gene Expression Profiling, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance. https://app.cochat.ai/papers/10.1016/s0002-9440(10)63112-4
The paper
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., Reuter, V., & Gerald, W. L. (2004). Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)63112-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.